Why I’d buy AstraZeneca plc over this soaring growth stock

Harvey Jones says AstraZeneca plc (LON: AZN) could hit new peaks and put this biotechnology upstart in its place.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

These two stocks both operate in the pharmaceutical sector but could not be more different. One is a growth minnow, the other an income behemoth. But they have risk in common. One is quite evidently high-risk, the other has become unexpectedly risky. Which would you buy?


Bioventix (LSE: BVXP) manufactures and supplies high affinity sheep monoclonal antibodies for use in diagnostic applications such as clinical blood testing. Founded in 2003, the Surrey-based biotechnology company has traded on AiM since 2014, and has a current market capitalisation of £125m.

Recent share price performance has been meaty, with the stock up 275% in the past three years. Last year it was booming thanks to continued demand for its monoclonal antibodies, favourable currency shifts and encouraging developments from project partner Siemens Healthcare Diagnostics on its new troponin antibody. Some reckon it could even be the UK’s most exciting investment opportunity.

Peak or plateau?

Bioventix posted more good news last month, raising annual pre-tax profits more than a third due to rising sales of its vitamin D antibody. Annual revenue rose 30% to £7.2m and its cash balance climbed from £5.3m to £6.1m. However, it also warned that the vitamin D market would plateau in the near future, and may only record a “modest further increase” in the coming fiscal period.

I have personally developed antibodies against soaring biotech companies because of the danger that you come to the party too late! My concerns are magnified by the fact that after three years of double-digit EPS growth around the 40% mark, City forecasters are pencilling in a drop of 18% in the year to 30 June 2018. A forward valuation of 26 times earnings is also a concern. After the peak, the plateau.

Mystic men

Pharmaceutical giant AstraZeneca (LSE: AZN) is a very different creature with a current market cap of nearly £66bn. It has also done well lately, its share price up 77% over five years, and almost 15% over three months. However, it has been a bumpy ride, with the stock plunging 15% in July after the failure of its Mystic drug, a first-line chemotherapy alternative.

I wrote at the time that this was a buying opportunity for the brave and it has since rallied strongly, so yay me. You need to understand the ongoing risks, though. Investors have had to be patient with the company, and put a lot of faith in CEO Pascal Soriot, who is developing the company’s long-term pipeline of treatments.

Future shock

On Wednesday we had the good news that the US Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for adult patients with mantle cell lymphoma (MCL), combined with disappointing results for new treatment tralokinumab aimed at patients with severe asthma. You can expect a lot more of this.

AstraZeneca’s EPS have fallen in four out of the past five years. Another 13% drop is forecast for this year, followed by a measly 1% rise in 2018. The prize, however, is further down the line, with Soriot projecting revenues of more than $45bn by 2023, now just six years away. That’s quite a leap from 2017’s projected $16.06bn. The forecast yield of 4.2% should help settle your nerves as you wait to see if his strategy is a winner.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s why I think the Vodafone share price should be 110% higher

Reflecting on speculation, our writer believes there’s a case to be made for the Vodafone share price being more than…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

Is this dividend star also the best bargain in the FTSE 100?

This FTSE 100 stock pays a whopping 8%+ yield, looks very undervalued against its peers, and is set for stellar…

Read more »

Investing Articles

2 FTSE 100 stocks. One sublime, the other ridiculous

Our writer doesn’t understand the appeal of Ocado. But looking at the grocer’s latest results makes him see the attraction…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Down 18% in a year, what’s next for the Greatland Gold (GGP) share price?

The Greatland Gold share price has disappointed over the past 12 months. Our writer asks whether the company’s latest update…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

With 30% annual returns for a decade, I’m buying this for my Stocks & Shares ISA

Oliver Rodzianko has been looking for a new investment for his Stocks and Shares ISA. Here's one he's decided is…

Read more »

Investing Articles

These were the FTSE 100’s dogs and stars in February

The FTSE 100 limped along last month, but some Footsie shares soared while others slumped. Here are February's winners and…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

This £43bn of passive income is up for grabs today!

As a lover of passive income, I'm always on the lookout for extra cash. The good news is that these…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Is this my once-in-a-decade chance to buy these 2 beaten-down UK shares before they rocket?

The FTSE 100 has had a bumpy ride but these two UK shares have had it bumpier. Could now be…

Read more »